

BILBAO

SPAIN

Andreas Kovar

Bio



Andreas Kovar, Ph.D., F.C.P., studied Pharmacy at the University of Tübingen. After receiving his Ph.D. at the University of Tübingen, he held there a teaching position in Medicinal Chemistry. Subsequently, he did preclinical and clinical research on PK/PD correlations with a two-year scholarship of the DFG (German Research Foundation) at the University of Florida, Gainesville, USA in the labs of Hartmut Derendorf. In 1997 he joined Merck KGaA where he held various positions in research and clinical drug development such as Global Head Clinical Pharmacology and Pharmacokinetics for Merck Serono, Geneva and Vice President for Global Exploratory Medicine Merck in

Darmstadt. In 2014 he joined Sanofi Aventis as an Assoc. Vice President in Disposition, Safety and Animal Research. Since 2020 he holds the position as Head of Translational Medicine and Early Development in Frankfurt, Germany.

Andreas is an elected member of AGAH's Board of Regents since 2001 and in 2020-2022 he served as president of AGAH. He is a Fellow of Clinical Pharmacology of the American College of Clinical Pharmacology, has published >40 peer reviewed papers, articles, and book chapters and presented |>100 posters and presentations at scientific meetings and congresses.

Abstract

TNF α is a key driver in the pathogenesis of multiple auto-immune diseases (e.g. psoriasis, rheumatoid arthritis, inflammatory bowel disease), and regulates signalling via engagement with TNFR1 and TNFR2. SAR441566 is the first oral, small molecule TNFR1 signal inhibitor that entered clinical development. Early biomarker, population PK and E-R analyses confirmed favorable PK and PD across 8 phase 1 studies in healthy volunteers and patients. The application of MIDD is being used to guide dose selection for phase 2B.

However, don't judge too quickly—things are not always as they appear

